Education
About Us
Working with TipRanks
Follow Us
Arcellx Inc (ACLX)
NASDAQ:ACLX
ACLX Stock Chart & Stats
$68.80
-$3.36(-4.36%)
At close: 4:00 PM EST
$68.80
-$3.36(-4.36%)
Day’s Range― - ―
52-Week Range$47.86 - $94.07
Previous CloseN/A
Volume227.93K
Average Volume (3M)808.36K
Market Cap
$3.89B
Enterprise Value$3.91B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Feb 26, 2026EPS Estimate
-1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding57,822,872
10 Day Avg. Volume725,033
30 Day Avg. Volume808,359
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)9.03
Price to Sales (P/S)38.06
P/FCF Ratio-42.39
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$110.92Price Target Upside61.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manufacturing CapacityAn established manufacturing partnership lowers the risk of production delays and supports broad treatment center availability and rapid product turnaround, improving commercial launch prospects for anito-cel.
Regulatory OutlookFDA draft guidance endorsing minimal residual disease negativity and complete response as primary endpoints supports an accelerated approval pathway and increases the likelihood of priority review for the biologics license application for anito-cel.
Safety ProfileAnito-cel's D-Domain binder avoids antigen-independent tonic signaling and off-target CLDN9 activity, reducing the risk of delayed neurotoxicity and inflammatory side effects compared with traditional CAR-T binders.
Bears Say
Competitive LandscapePositive clinical results for BCMA bispecific therapies increase competitive pressure and could limit the commercial uptake and market share available to CAR-T therapies such as anito-cel.
Mechanistic UncertaintyEvidence linking CLDN9 to delayed neurotoxicity relies on tests with artificial protein overexpression, creating uncertainty that animal studies using physiological expression levels need to address.
Translational RiskSafety signals observed in laboratory studies are based on preclinical data and require clinical confirmation before concluding that reduced neurotoxicity will occur in patients.
Arcellx Inc News
ACLX FAQ
What was Arcellx Inc’s price range in the past 12 months?
Arcellx Inc lowest stock price was $47.86 and its highest was $94.07 in the past 12 months.
What is Arcellx Inc’s market cap?
Arcellx Inc’s market cap is $3.89B.
When is Arcellx Inc’s upcoming earnings report date?
Arcellx Inc’s upcoming earnings report date is Feb 26, 2026 which is in 14 days.
How were Arcellx Inc’s earnings last quarter?
Arcellx Inc released its earnings results on Nov 05, 2025. The company reported -$0.99 earnings per share for the quarter, missing the consensus estimate of -$0.983 by -$0.007.
Is Arcellx Inc overvalued?
According to Wall Street analysts Arcellx Inc’s price is currently Undervalued.
Does Arcellx Inc pay dividends?
Arcellx Inc does not currently pay dividends.
What is Arcellx Inc’s EPS estimate?
Arcellx Inc’s EPS estimate is -1.04.
How many shares outstanding does Arcellx Inc have?
Arcellx Inc has 57,822,872 shares outstanding.
What happened to Arcellx Inc’s price movement after its last earnings report?
Arcellx Inc reported an EPS of -$0.99 in its last earnings report, missing expectations of -$0.983. Following the earnings report the stock price went up 0.788%.
Which hedge fund is a major shareholder of Arcellx Inc?
Currently, no hedge funds are holding shares in ACLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcellx Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$110.92 (61.23% Upside)
$110.92 (61.23% Upside)
Blogger Sentiment
Bullish
ACLX Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 15.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 7.7%
Last 30 Days ▼ 7.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.82%
12-Months-Change
Fundamentals
Return on Equity
-47.18%
Trailing 12-Months
Asset Growth
-14.25%
Trailing 12-Months
Company Description
Arcellx Inc
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
ACLX Stock 12 Month Forecast
Average Price Target
$110.92
▲(61.23% Upside)
Technical Analysis
Protagonist Therapeutics
―
Apellis Pharmaceuticals
―
Immunovant
―
Beam Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
Currently, No data available
---